← Back to Episodes
PODCAST

Your £400 Supplements Are a Scam (And Other Wednesday Truths)

September 30, 2026·9:43·Episode 135

Quick Summary

Which? analyzed the most popular menopause supplements and found they're nutritionally equivalent to a standard multivitamin that costs twenty times less. This episode also covers an 18-year study connecting the age you reach menopause to long-term brain health, and a new non-invasive test that could spare thousands of women from uncomfortable procedures when they experience post-menopausal bleeding.

Your £400 Supplements Are a Scam (And Other Wednesday Truths)

0:000:00

Key Takeaways

  • ✦Popular menopause supplements costing £400+ per year contain the same key nutrients in similar amounts as a £22 standard multivitamin, according to Which? analysis.
  • ✦An 18-year longitudinal study found that the age at which a woman reaches menopause may be linked to her cognitive health decades later — suggesting menopause timing is about more than fertility.
  • ✦Earlier menopause (before the average age of around 51) was associated with higher risk of cognitive decline in the study, though the research is observational and cannot prove cause and effect.
  • ✦UK researchers have developed a test using urine and vaginal fluid samples that could rule out womb cancer in lower-risk women who experience post-menopausal bleeding — potentially replacing invasive hysteroscopies for many.
  • ✦Post-menopausal bleeding always warrants a conversation with a doctor. It's usually not cancer, but it needs to be checked.

Episode Script

Thanks Toni. We've got a good one today.

It's Wednesday, which means nothing thematically, but we're going to call it Myth-Busting Monday anyway — because sometimes the calendar is wrong and the content is right.

Three things on the table. A consumer watchdog just did the work that probably should have been done years ago on menopause supplements. There's an 18-year study on menopause timing and brain health that's worth actually reading past the headline. And UK researchers have developed a test that could change what happens when a postmenopausal woman shows up at her doctor's with bleeding. We'll go through all of it.


The supplement story first, because it's infuriating in a very specific, very documentable way.

Which? — that's the UK's main consumer watchdog organization — analyzed popular menopause supplements. These are the products marketed specifically to women over 45, the ones with names that imply they understand what your body is going through, the ones with elegant packaging and ingredient lists that sound impressively targeted. Some of them cost more than £400 a year.

Which? compared them to a standard multivitamin that costs about £22 a year.

Same nutrients. Similar amounts. Twenty times the price.

That's the finding. Not that menopause supplements are slightly overpriced. Not that they're marginally less effective than advertised. That you are, in many cases, paying £400 for something nutritionally equivalent to what you'd get from the basic bottle at the pharmacy.

This matters for a specific reason that goes beyond the money — although the money matters too. The marketing around these products is doing something clever and kind of insidious. It takes the very real experience of perimenopause and menopause — the fatigue, the brain fog, the hot flashes, the joint aches — and presents itself as the answer to all of it. The product exists in a space where women are often undertreated by conventional medicine, where they've been dismissed or given inadequate information, and where they're genuinely looking for something that might help. That's not a coincidence. That's a business model.

And when Which? actually opens up the products and looks at what's inside, the emperor has no clothes. The quantities of key nutrients don't match the claims. The price doesn't match the contents.

Now — and this is worth saying clearly — this doesn't mean supplements are always useless. Some women have genuine nutritional deficiencies. Some nutrients do have research behind them for specific symptoms. Magnesium and sleep, for instance, has a real evidence base worth looking at. Vitamin D matters for bone health, particularly in populations that don't get much sun. If you're working with a doctor or a registered dietitian and you're taking something with a specific evidence-based reason behind it, that's a different conversation.

But the broad category of "menopause supplement" — the branded, premium-priced products that promise to address your whole symptom picture — that category just took a significant hit from people who actually checked. My position on this is straightforward: save the £378.


The brain health study is doing something more interesting and more complicated, so it deserves a bit more unpacking.

An 18-year longitudinal study — published and covered by ScienceAlert — found that the age at which a woman reaches menopause may be connected to her cognitive health decades later. Women who went through menopause earlier, before the average age of around 51, showed higher rates of cognitive decline over the study period.

Before we go anywhere with this, the methodology note is important: this is observational research. It followed women over time and looked for patterns, but it can't tell us that early menopause causes cognitive decline. It can tell us there's an association. Those are genuinely different things.

That said, 18 years is a serious study duration. This isn't a six-week trial or a questionnaire sent to 200 people. Longitudinal data over nearly two decades has a lot more weight than we give it credit for in the news cycle, where every study gets the same "researchers found" treatment regardless of how robust the design actually is.

The working hypothesis — and this is where the biology gets interesting — is that estrogen has protective effects on the brain. It's involved in how neurons communicate, how blood flows to the brain, how certain memory systems function. If estrogen drops earlier and stays low for longer, the thinking goes, the brain has less of that protection for more years. That's the mechanism that researchers are pointing to, though it's not fully proven.

What this study doesn't tell us: whether hormone therapy changes the picture. That's one of the big open questions in menopause research right now, and it's genuinely unsettled. Some studies suggest that HRT started close to the time of menopause — what researchers call the "timing hypothesis" or the "critical window" — may preserve some cognitive protection. Others show more mixed results. It's one of those areas where the honest answer is that the evidence is still coming in, and anyone who tells you it's settled is selling you certainty they don't have.

What the study does tell us is that menopause timing isn't just a fertility question. For a long time, the conversation around early menopause focused almost entirely on bone health and heart health, with fertility as the headline concern for younger women. The brain dimension is getting more research attention now, and this study adds to the case that it should.

If you went through menopause before your mid-forties, this is information worth bringing to a doctor — not to panic, but to have a fuller conversation about what the research says and what, if anything, that means for your care. The kind of conversation that a tool like OpenEvidence exists for, honestly — the kind of synthesized clinical evidence that a GP can pull up in an appointment rather than going off 20-year-old training.


The third story is the one I want more people to know about, because it involves a symptom that doesn't get discussed clearly enough.

If you're postmenopausal and you experience bleeding — any bleeding — that warrants a call to your doctor. Full stop. Most of the time it's not cancer. But postmenopausal bleeding is one of the warning signs for womb cancer, which is also called endometrial cancer, and the current diagnostic pathway is uncomfortable enough that some women put off going in.

Right now, if a woman presents with postmenopausal bleeding, the standard workup often involves a transvaginal ultrasound and, for many women, a hysteroscopy — which is a camera inserted through the cervix to look at the inside of the uterus. It can be done without general anesthetic, which sounds reassuring until you read any description of what it actually involves for women who find it painful. And a meaningful number of women do.

UK researchers have developed a test that could change this pathway for lower-risk women. It uses urine and vaginal fluid samples — collected non-invasively — and can rule out womb cancer in women whose other indicators suggest they're at lower risk. The goal isn't to replace the full diagnostic workup for everyone. It's to give doctors a way to say, with confidence, that certain women don't need to go through a hysteroscopy — sparing them a painful procedure and freeing up clinical capacity for women who do need the more invasive assessment.

This is still in the research and development stage. It's not sitting in your GP's office yet. But the results are promising enough that it's being taken seriously, and the clinical problem it's solving is real.

The broader point — and this is the one I want to sit with for a second — is that womb cancer is actually one of the more common gynecological cancers in the UK and in the US, and it has a relatively good prognosis when caught early. Postmenopausal bleeding is one of its earlier warning signs. The barrier between that symptom and a diagnosis shouldn't be a procedure that a significant number of women find traumatic enough to avoid. If a non-invasive screening option can lower that barrier, that's not a small thing. That's the difference between a cancer caught in stage one and a cancer caught later, for some women.

Go get the bleeding checked. And watch this test — because it's the kind of development that quietly changes outcomes at scale.


Sources curated automatically by the Hot Flasher pipeline.

Hot Flasher provides informational content only and does not constitute medical advice. Always consult a qualified healthcare provider for medical concerns.